Abstract
Objective
Exact determination of localization and extent of peritoneal carcinomatosis (PC) before peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) is crucial for the clinical outcome. Our study compares dynamic contrast enhanced 3D MRI (T1wDCE) and 18F-FDG PET/CT regarding diagnostic accuracy in correlation with surgical exploration (SE) and histological (HI) results.
Materials and methods
15 patients with PC were examined on a 1.5T MRI and 16 slice PET/CT. MRI: coronal T1wDCE covering the complete abdomen (0.15 mmol Gd-chelate/kg BW, 2000 mL mannitol solution p.o., 40 mg buscopan i.v.). PET-CT: contrast enhanced 16slice CT (120 mL ultravist 370 i.v., 1000 mL mannitol solution p.o., 40 mg buscopan i.v.), PET: 350 MBq 18-FDG i.v., 3 min acquisition time/bed, 60 min after tracer injektion). Assessment by two independent, experienced observers in correlation with results of SE and HI for each abdominal segment based on the peritoneal cancer index (PCI) proposed by Sugarbaker and co-authors.
Results
MRI and PET/CT provided reliable detection of PC. One patient had to be excluded from statistical analysis. In summary, 182 segments were assessed (13/patient, 14 patients, one patient excluded from statistical analysis). PC was found in 118 by MRI, 124 by PET/CT. 4 segments were classified false positive for MRI, 2 for PET/CT. False negative segments (MRI: 17, PET/CT: 9) did not result in irresectability. Positive predictive value for PC/segment was 97/98%, negative predictive value 73/84%, sensitivity 87/93%, specificity 92/96%, and diagnostic accuracy 88/94% (MRI/PET/CT).
Conclusion
With high diagnostic accuracy for PC of both, MRI and PET/CT, PET/CT provides better diagnostic accuracy and especially better NPV.
Similar content being viewed by others
References
Sadeghi B, Arvieux C, Glehen O, et al. (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363
Pyrhoenen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591
Hamilton T, Lanuke K, Mack LA, Temple WJ (2011) Long-term follow-up in the treatment of peritoneal carcinomatosis. Am J Surg 201(5):650–654
Raue W, Tsilimparis N, Langelotz C, et al. (2011) Initial results after implementation of multimodal treatment for peritoneal malignancies. Acta Chir Belg 111(2):68–72
Gill RS, Al-Adra DP, Nagendran J, et al. (2011) Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 104:692–698
Esquivel J, Elias D, Baratti D (2008) Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 98:263–267
Testa A, Ludovisi M, Mascilini F, et al. (2011) Ultrasound evaluation of intra-abdominal sites of disease to predict the likelihood of suboptimal cytoreduction in advanced ovarian cancer: a prospective study. Ultrasound Obstet Gynecol 39:99–105
Forstner R (2007) Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol 17:3223–3246
Pfannenberg C, Koenigsrainer I, Aschoff P, et al. (2009) (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 16:1295–1303
Low RN, Barone RM, Lacey C, et al. (1997) Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium containing contrast agents compared with unenhanced MR imaging and CT. Radiology 204:513–520
Low RN (2007) MR imaging of the peritoneal spread of malignancy. Abdom Imaging 32:267–283
Low RN, Sigeti JS (1994) MR imaging of peritoneal disease: comparison of contrast enhanced fast multiplanar spoiled gradient recalled and spin echo imaging. Am J Roentgenol 163:1131–1140
Glaspy JA, Hawkins R, Hoh CK, Phelps ME (1993) Use of positron emission tomography in oncology. Oncology 7:41–55
Kole AC, Nieweq OE, Pruim J, et al. (1998) Detection of unknown occult primary tumors using positron emission tomography. Cancer 82:1160–1166
Chopra S, Laurie LR, Chintapalli KN, Valente PT, Dodd GD 3rd (2000) Primary papillary serous carcinoma of the peritoneum: CT-pathologic correlation. J Comput Assist Tomogr 24:395–399
Hideo M, Aoki J, Taketomi A, Sato N, Endo K (2004) Serous surface papillary carcinoma of the peritoneum: clinical, radiologic and pathologic findings in 11 patients. Am J Roentgenol 183:923–928
Furukawa T, Ueda J, Takahashi S, et al. (1999) Peritoneal serous papillary carcinoma: radiological appearance. Abdom Imaging 24:78–81
Stafford-Johmson DB, Bree RL, Francis IR, Korobkin M (1998) CT appearance of primary serous carcinoma of the peritoneum. Am J Roentgenol 171:687–689
Zissin R, Hertz M, Shapiro-Feinberg M, et al. (2001) Primary serous papillary carcinoma of the peritoneum: CT findings. Clin Radiol 56:740–745
Brown G, Kirkham A, Williams GT, et al. (2004) High-resolution MRI of the anatomy important in total mesorectal excision of the rectum. Am J Roentgenol 182:431–439
De laco P, Musto A, Orazi L, et al. (2010) FDG-PET/CT in advanced ovarian cancer staging: Value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol 80:e98–e103
Berthelot C, Morel O, Girault S, et al. (2011) Use of FDG-PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy. Nucl Med Commun 32:23–29
Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH (1993) Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer 72:1631–1636
Sala E, Kataoka M, Pandit-Taskar N, et al. (2010) Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients’ survival. Radiology 257:125–134
Rakheja R, Makis W, Hickeson M (2011) Extraovarian primary peritoneal carcinoma: staging with 18F-FDG PET/CT. Abdom Imaging. doi:10.1007/s00261-011-9722-0
Funicelli L, Travaini LL, Landoni F, et al. (2010) Peritoneal carcinomatosis from ovarian cancer: the role of CT and [18F]FDG-PET/CT. Abdom Imaging 35:701–707
Marin D, Catalano C, Baski M, et al. (2010) 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdom Imaging 35:694–700
Iafrate F, Ciolina M, Sammartino P, et al. (2011) Peritoneal carcinomatosis: imaging with 64-MDCT and 3T MRI with diffusion-weighted imaging. Abdom Imaging [Epub]
Dromain C, Leboulleux S, Auperin A, et al. (2008) Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging 33:87–93
Low RN, Semelka RC, Worawattanakul S, Alzate GD, Sigeti JS (1999) Extrahepatic abdominal imaging in patients with malignancy: comparison of MR imaging and helical CT with subsequent surgical correlation. Radiology 210:625–632
Priest AN, Gill AB, Kataoka M, et al. (2010) Dynamic contrast-enhanced MRI in ovarian cancer: initial experience at 3 tesla in primary and metastatic disease. Magn Reson Med 63:1044–1049
Satoh Y, Ichikawa T, Motosugi U, et al. (2011) Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT diffusion-weighted MRI and contrast-enhanced MDCT. Am J Roentgenol 196:447–453
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Klumpp, B.D., Schwenzer, N., Aschoff, P. et al. Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI. Abdom Imaging 38, 64–71 (2013). https://doi.org/10.1007/s00261-012-9881-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-012-9881-7